Intellia Therapeutics IPO Research Information

Intellia Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Intellia Therapeutics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Intellia Therapeutics	NTLA - NASDAQ	Priced at $18.00	$18.00	$22.00	6 million	5/6/2016
Underwriter(s): Credit Suisse, Jefferies, Leerink Partners
Co-Manager(s): Wedbush PacGrow
Industry: Health Care
Filing(s): Filed 2016-04-11 Terms Added 2016-04-27

Intellia Therapeutics Quote & Chart - Click for current quote - NTLA

About Intellia Therapeutics (adapted from Intellia Therapeutics prospectus):
They are a leading gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "NTLA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.